Ortwin Gierhake
This page summarises the Hong Kong Securities and Futures Commission (SFC) public register record for Ortwin Gierhake, a licensed Responsible Officer with CE reference AVT234. Currently licensed at 1 firm(s): Marex Financial Services Hong Kong Limited. Active regulated activities: Type 1 - Dealing in securities; Type 2 - Dealing in futures contracts. This person has 14.8 years of SFC licence history. Total licence records on file: 10.
Information
- LinkedIn:
- Email:
Licence history
| Firm | Role | Regulated activity | From | To |
|---|---|---|---|---|
| Marex Financial Services Hong Kong Limited | RO | Type 1 - Dealing in securities | 2024-02-19 | present |
| Marex Financial Services Hong Kong Limited | RO | Type 2 - Dealing in futures contracts | 2024-02-19 | present |
| Marex Financial Services Hong Kong Limited | Rep | Type 1 - Dealing in securities | 2023-12-13 | 2024-02-19 |
| Marex Financial Services Hong Kong Limited | Rep | Type 2 - Dealing in futures contracts | 2023-12-13 | 2024-02-19 |
| Xeram and Company (Asia) Limited | RO | Type 1 - Dealing in securities | 2019-05-17 | 2023-11-30 |
| Xeram and Company (Asia) Limited | RO | Type 2 - Dealing in futures contracts | 2019-05-17 | 2023-11-30 |
| Nomura International (Hong Kong) Limited 野村國際(香港)有限公司 |
Rep | Type 6 - Advising on corporate finance | 2014-07-18 | 2018-04-10 |
| Nomura International (Hong Kong) Limited 野村國際(香港)有限公司 |
Rep | Type 2 - Dealing in futures contracts | 2012-05-04 | 2018-04-10 |
| Nomura International (Hong Kong) Limited 野村國際(香港)有限公司 |
Rep | Type 1 - Dealing in securities | 2010-08-30 | 2018-04-10 |
| Nomura International (Hong Kong) Limited 野村國際(香港)有限公司 |
Rep | Type 4 - Advising on securities | 2010-08-30 | 2018-04-10 |
Worked alongside
The 20 closest colleagues, strongest tie first — individuals licensed at the same firm as Ortwin Gierhake during overlapping periods. Ranked by how long they overlapped and how similar their regulated activities were, with shared time at a smaller firm weighted more than at a large one. See the detailed formula.